SB-649915-B, a Novel 5-HT1A/B Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test

@article{Starr2007SB649915BAN,
  title={SB-649915-B, a Novel 5-HT1A/B Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test},
  author={K. Starr and G. Price and J. Watson and P. J. Atkinson and R. Arban and Sergio Melotto and L. Dawson and J. J. Hagan and N. Upton and M. Duxon},
  journal={Neuropsychopharmacology},
  year={2007},
  volume={32},
  pages={2163-2172}
}
  • K. Starr, G. Price, +7 authors M. Duxon
  • Published 2007
  • Medicine, Psychology
  • Neuropsychopharmacology
  • Preclinically, the combination of an SSRI and 5-HT autoreceptor antagonist has been shown to reduce the time to onset of anxiolytic activity compared to an SSRI alone. In accordance with this, clinical data suggest the coadministration of an SSRI and (±) pindolol can decrease the time to onset of anxiolytic/antidepressant activity. Thus, the dual-acting novel SSRI and 5-HT1A/B receptor antagonist, SB-649915-B, has been assessed in acute and chronic preclinical models of anxiolysis. SB-649915-B… CONTINUE READING
    Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
    • 205
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 88 REFERENCES
    SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
    • 14
    Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety.
    • 55